As mentioned above, enhanced insulin receptor signaling has been one strategy for clinical treatments for patients with Alzheimer's disease [150-152] and schizophrenia [148,149], although the underlying mechanism is not clear. The gene discussed is INSR; the disease is early-onset autosomal dominant Alzheimer disease.